Irritable Bowel Syndrome (IBS) Treatment Market Report

Irritable Bowel Syndrome (IBS) Treatment Market Analysis, Market Size, Disease Type Analysis, Drug Class Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Published Date: ---
  • Base Year for Estimate:
  • Report ID: GVR5654
  • Format: Electronic (PDF)
  • Historical Data:
  • Number of Pages: 0

Global irritable bowel syndrome (IBS) treatment market is projected to increase at a substantial rate over the forecast period. Increasing prevalence of IBS and rising label extension of existing products are expected to drive the market. Furthermore, increasing uptake of IBS drugs and commercialization of new products are further projected to accelerate the growth over the forecast period.

IBS is the most common functional gastrointestinal disorder with global prevalence rate generally ranging between 10-15%. Among patients around 25% of people have severe IBS, 35% moderate IBS, and 40% mild IBS. Most of the people can’t identify IBS symptoms, still it is one of the most common disorders observed by doctors. Not all people with IBS symptoms seek treatment for their symptoms. However, there are around 2.4-3.5 million yearly physician visits for IBS in the U.S. alone. IBS is one of the most common disorder detected by gastroenterologists and holds up to 12% of total visits to primary care providers. Globally, IBS affects around 60-65% of females and 35-40% of males.

IBS is divided into three main types, diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), and mixed-presentation (IBS-M). Plecanatide, linaclotide, lubiprostone, alosetron, and rifaximinare some of the highly recommended drugs for the treatment of IBS. The rising uptake of products such as Linzess (linaclotide), and Trulance (Plecanatide) are further estimated to drive the market over the forecast period.

North America is the largest revenue generating region owing to the presence of significant market players, well-established healthcare infrastructure, and high patient awareness. Asia Pacific is estimated to witness the fastest growth during the forecast period due to high prevalence rate of IBS and unmet clinical needs.

The key players in the IBS treatment market are Ironwood Pharmaceuticals, Allergan, Astellas, Takeda, Sucampo, Salix, AstraZeneca, Sebela Pharmaceuticals, Synergy Pharma, Ardelyx, GlaxoSmithKline, Sumitomo Dainippon Pharma, and Synthetic Biologics. The players are adopting different marketing strategies such as awareness programs, technological advancement, increasing number of collaborations, geographic expansion, R&D activities, and introducing new products to upsurge their market share.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified